Immuneering AI Stock Analysis
Want to see IMRX full AI Analyst Report?
Immuneering (IMRX) AI Stock Analysis
Immuneering
(NASDAQ:IMRX)
The score is primarily weighed down by weak financial performance—zero revenue, sizable ongoing losses, and persistent cash burn (with an extremely negative TTM cash flow figure in the provided data). Technicals are mixed with a small near-term improvement (above the 20-day average) but a still-bearish longer-term trend (below 50/100/200-day averages). Valuation is hard to assess given negative earnings and no dividend yield support.
Immuneering (IMRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $240.27M
- Dividend Yield
- ―
- Average Volume (3M)
- 709.75K
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 1.64
- Revenue Growth
- ―
- EPS Growth
- 42.34%
- Country
- US
- Employees
- 65
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immuneering Business Overview & Revenue Model
Company Description
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-M...
Immuneering Earnings Call Summary
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Immuneering Corporation's third-quarter 2025 conference call, CEO Benjamin Zeskind highlighted notable guidance for the company's development plans, focusing on their Phase IIa trial of atebimetinib. Immuneering plans to prioritize atebimetinib in combination with gemcitabine nab-paclitaxel due to its impressive 86% overall survival rate at nine months in first-line pancreatic cancer patients, compared to the standard 47%. The company aims to present updated results at a major medical meeting in 2026. Financially, Immuneering strengthened its position with $225 million in cumulative financing, extending its cash runway into 2029, which supports the planned pivotal Phase III trials and other developments. Additionally, the company is preparing to dose the first patient in a pivotal trial in mid-2026 and has planned studies with Regeneron and Eli Lilly, indicating broad potential for atebimetinib across various cancer types.
Immuneering Financial Statement Overview
Summary
Overall financial profile is weak: revenue has fallen to zero in recent periods and losses remain sizable (TTM net income about -$66.5M). Cash flow is a major headwind with persistent negative operating/free cash flow and an extreme TTM deterioration in cash flow figures (noted as a possible anomaly, but still concerning based on provided data). The key offset is a relatively strong balance sheet with very low leverage (~$3.5M debt vs. ~$168.7M equity; ~0.02 debt-to-equity).
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 316.95K | 2.08M |
| Gross Profit | -983.22K | -698.89K | 0 | 0 | 158.83K | 926.89K |
| EBITDA | -72.11M | -55.67M | -63.69M | -58.06M | -51.47M | -33.68M |
| Net Income | -66.50M | -56.02M | -61.04M | -53.47M | -50.51M | -33.54M |
Balance Sheet | ||||||
| Total Assets | 182.56M | 231.99M | 52.71M | 102.58M | 122.37M | 166.70M |
| Cash, Cash Equivalents and Short-Term Investments | 145.41M | 172.83M | 36.14M | 85.67M | 105.52M | 149.20M |
| Total Debt | 3.53M | 3.82M | 4.16M | 4.46M | 4.84M | 5.36M |
| Total Liabilities | 13.88M | 13.50M | 11.33M | 12.01M | 12.52M | 10.72M |
| Stockholders Equity | 168.68M | 218.48M | 41.39M | 90.58M | 109.85M | 155.98M |
Cash Flow | ||||||
| Free Cash Flow | -61.81M | -45.49M | -55.08M | -49.31M | -44.84M | -30.91M |
| Operating Cash Flow | -61.56M | -45.34M | -55.00M | -48.97M | -44.10M | -30.85M |
| Investing Cash Flow | -107.84M | -88.74M | 26.43M | 7.30M | 41.83M | -75.62M |
| Financing Cash Flow | 68.02K | 226.58M | 5.30M | 28.44M | 19.00K | 144.26M |
Immuneering Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRX, the sentiment is Negative. The current price of 3.71 is below the 20-day moving average (MA) of 3.73, below the 50-day MA of 4.00, and below the 200-day MA of 4.74, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.40 is Neutral, neither overbought nor oversold. The STOCH value of 58.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMRX.
Immuneering Risk Analysis
Immuneering disclosed 90 risk factors in its most recent earnings report. Immuneering reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksImmuneering Peers Comparison
Overall Rating
IMRX47Neutral
LRMR46Neutral
RCKT42Neutral
AURA41Neutral
IVVD41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $240.27M | -3.60 | -33.91% | ― | ― | 42.34% | |
| 46Neutral | $313.73M | -1.52 | -137.39% | ― | ― | -27.00% | |
| 42Neutral | $256.82M | -16.43 | -5.34% | ― | ― | 93.49% | |
| 41Neutral | $739.97M | -4.26 | -64.69% | ― | ― | 13.33% | |
| 41Neutral | $171.58M | -1.48 | -59.73% | ― | 26.30% | 59.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMRX | Immuneering Corp. Class A | 3.71 | -3.44 | -48.11% | |
| LRMR | Larimar Therapeutics, Inc. | 3.02 | -0.37 | -10.91% | |
| RCKT | Rocket Pharma | 2.30 | -0.64 | -21.77% | |
| IVVD | Invivyd | 0.58 | -1.95 | -77.00% | |
| AURA | Aura Biosciences Inc | 7.11 | 1.70 | 31.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
